Pyxis Oncology, Inc. Number of Reportable Segments
Pyxis Oncology, Inc. (PYXS) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-13
- Pyxis Oncology, Inc. number of reportable segments for the quarter ending 2026-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- Pyxis Oncology, Inc. number of reportable segments for the quarter ending 2025-03-31 was 1.00 Segment.
- Pyxis Oncology, Inc. number of reportable segments for fiscal 2025 was 1.00 Segment, a 0.00% change from fiscal 2024.
- Pyxis Oncology, Inc. number of reportable segments for fiscal 2024 was 1.00 Segment.
- Pyxis Oncology, Inc. number of reportable segments for fiscal 2021 was 1.00 Segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-03-23 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-03-18 | |||
| 2021-12-31 | 1.00 Segment 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |